Improved blood glucose disposal and altered insulin secretion patterns in adenosine A(1) receptor knockout mice

Gary K Yang1, Bertil B Fredholm, Timothy J Kieffer

  • 1Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Insights

A(1) receptors influence pancreatic insulin release patterns, impacting glucose homeostasis. Disrupting these receptors may affect type 2 diabetes development and treatment strategies.

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Diabetes Pathophysiology

Background:

  • Type 2 diabetes mellitus (T2DM) involves insufficient insulin secretion from pancreatic β-cells.
  • Therapeutic strategies for T2DM aim to boost insulin output or enhance insulin sensitivity.
  • The role of A(1) receptors in glucose regulation requires further investigation.

Purpose of the Study:

  • To investigate the function of A(1) receptors in maintaining glucose homeostasis.
  • To determine the impact of A(1) receptor deficiency on insulin secretion and glucose tolerance.
  • To explore the role of A(1) receptors in diet-induced glucose intolerance.

Main Methods:

  • Utilized A(1) receptor knockout mice (A(1)R(-/-)) and wild-type controls.
  • Assessed glucose tolerance, insulin release, insulin sensitivity, weight gain, and food intake.
  • Analyzed plasma glucagon levels and performed pancreas perfusion studies under varying glucose conditions and high-fat diet (HFD) feeding.

Main Results:

  • A(1)R(-/-) mice showed improved glucose tolerance but similar insulin release and sensitivity compared to controls.
  • A(1)R(-/-) mice lacked the typical decrease in plasma glucagon post-glucose challenge.
  • Pancreas perfusion revealed altered insulin release patterns in A(1)R(-/-) mice, with abolished regularity under HFD conditions.

Conclusions:

  • A(1) receptors are crucial for regulating the temporal dynamics of insulin release.
  • Dysregulation of A(1) receptor-mediated insulin secretion patterns may contribute to T2DM pathogenesis.
  • Targeting A(1) receptors could offer novel therapeutic avenues for managing glucose intolerance.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...